Efficacy and Safety of PEG-rhG-CSF in the Prevention of Neutropenia After Chemo in Pts With Gynecological Malignancies

Inclusion Criteria: * Ages 18-70 * Weight ≥45 kg * ≤2 lines chemotherapy or postoperative adjuvant chemotherapy patients with cervical cancer, ovarian cancer and endometrial cancer * Receive paclitaxel combined with platinum three weeks per cycle of chemotherapy * With an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1 * Expected survival time of \> 3 months * Main organ functions meet the following criteria: 1. Hb≥75g/L; WBC≥3.0×109/L; ANC≥1.5×109/L; PLT≥80×109/L; 2. APTT-ULN≤10s; PT-ULN≤3s; TT-ULN≤3s; 3. ALT≤2.5×ULN; AST≤2.5×ULN; TBIL≤2.5×ULN; 4. BUN≤1.5×ULN; Cr≤1.5×ULN; UA≤1.5×ULN；Creatinine clearance≥40mL/min; 5. without obvious cardiac dysfunction * Provided consent for participation Exclusion Criteria: * With uncontrollable infections or receive systemic antibiotics within 72 hours prior to chemotherapy * Pregnant or lactating women * Received bone marrow or hematopoietic stem cell transplantation within the past 3 months * Concurrent chemoradiotherapy * Presence of hematological disorders: systemic lupus erythematosus, sjogren's syndrome, rheumatic autoimmune disease, mixed and hoof tissue disease, autoimmune hemolytic anemia, leukopenia , chronic granulocyte leukemia, bone marrow dysplasia syndrome, aplastic anemia, congenital and idiopathic neutropenia, myelodysplastic syndrome, cyclic neutropenia, primary and secondary thrombocytopenic purpura, etc * Presence of risk of thrombus or high risk of clotting * Presence of psychosis, neurological disease or brain metastases from tumors * Presence of uncontrollable complicated disease including symptomatic congestive heart failure, uncontrollable hypertension, unstable angina pectoris, active peptic ulcer, or hemorrhagic disease * Presence of uncontrollable infectious diseases, active viral hepatitis, tuberculosis, HIV * Allergic to recombinant human granulocyte stimulating factor or other biological products of E. coli origin * Received clinical trials within 1 month prior to enrollment